According to a new report from the @AmericanCancer #CRC diagnoses are shifting rapidly to more advanced diseases and in younger people. Today, Freenome is attending a meeting at The White House for #CancerMoonshot. Watch live: https://t.co/0r2lWbG4K3

From @AmericanCancer: colorectal cancer is the 3rd most commonly diagnosed cancer for both men and women, estimating >150K CRC cases in the US in 2024. We are building blood tests designed to screen for CRC, aiming to help patients detect CRC earlier in its more treatable stages.

Freenome was founded in 2014, and now in 2024, we are entering in our next decade with a refreshed look. We remain committed to outpacing cancer through early detection, by combining the latest in science and AI to create accessible screening tests. Visit https://t.co/Z0PjGd0WWC

In observance of Colorectal Cancer Awareness Month, we reaffirm our commitment to battling colorectal cancer (CRC) through our work building early cancer detection blood tests. Throughout March, we'll share more about CRC, and show the potential of #earlydetection to save lives.

Announcing a $254 million funding round led by @Roche alongside existing and new investors. This will accelerate Freenome’s efforts to advance early cancer detection. Full PR: https://t.co/6Fkbnd6JhS

The @LungAssociation highlights that only 4.5% of high-risk individuals nationally are screened for #LungCancer. This data demonstrates the need for widespread, effective screening. Our focus is on bridging these screening gaps through innovative, non-invasive testing methods.

Those aged 50-80 years with a history of 20+ pack-years of smoking are now considered high risk for lung cancer, as per the updated USPSTF guidelines. This broadened criterion has increased the number of people eligible for screening, especially among women and Black Americans.

At Freenome we not only have employees that bring technical skill, creative vision, and deep empathy to their work, but we have a team that represents all of these attributes. It is a key to our continued progress toward the creation of #EarlyCancerDetection blood tests.

This February, we observe National Cancer Prevention Month. Our PROACT Lung and PREEMPT CRC® clinical studies—together involving over 50,000 participants across 300+ locations—demonstrate our dedication to early cancer detection. Learn more here: https://t.co/rsKHTHgxB5

When we catch #cancer early, we have a greater chance of beating it. In the case of colorectal cancer, for instance, early diagnosis leads to a 90% survival rate. Learn more about the importance of #earlycancerdetection on our website: https://t.co/WiwOlSjGFe

As we observe Dr. Martin Luther King Jr. Day, Freenome honors the legacy of a visionary leader who championed civil rights and equality. In our work, healthcare equity is top of mind, especially as we strive to ensure inclusivity and representation in our clinical trials.

Introducing Dheeraj Talreja, Senior Vice President of Marketing and Commercial Strategy. His comments echo our beliefs about the right way to conduct clinical research. We work to achieve diverse representation, to make informed decisions, and to foster long-term relationships.

Do you share Dr. Lin's belief that #cancer can be solved in our lifetime? We're seeking to fill the role of Senior Network Engineer with a candidate who shares our dream of changing the cancer treatment trajectory for good. https://t.co/a7kq3ATN9G

Happy New Year from Freenome! As we step into 2024, we are filled with enthusiasm, hope, and our dedication to fulfilling the promise of early cancer detection. We wish everyone a year of health and joy.

Thank you to @MedTechDive for featuring the initiation of our PROACT LUNG Clinical Study. Through PROACT LUNG, we aim to validate the clinical efficacy of our blood test for the early detection of lung cancer. More below: https://t.co/nSKRlCHJK6 #CancerResearch #ClinicalTrials

What if you could detect lung cancer early through a blood test? We’ve set out to realize this possibility with our just-initiated PROACT LUNG study. Our goal is to validate the clinical efficacy of our blood test for the early detection of lung cancer. https://t.co/THSDvi0HYy

With over 100 #cancer types, each with distinct biological signals, we acknowledge that relying solely on one marker can't capture the whole picture. Enter #multiomics. Every cancer's voice is unique, and knowing where and how to listen is essential. https://t.co/XQJJJZYR20

At Freenome, the Vallania Study stands as a heartfelt homage. Named in reverence for Natalia Vallania—the study embodies our ethos of infusing the spirit of resilience into our relentless drive for early cancer detection. More: https://t.co/M0e2YW4H75

We look back today on @EliseReuter's @MedTechDive Q&A with our CEO, Mike Nolan. In the article, he states, "For [Freenome], the competition is cancer. We're really driven to beat cancer. That's the motivation." How's that for a mission? https://t.co/nKXTr1apG3

Our #multiomics platform combines tumor and non-tumor signals with #MachineLearning to detect cancer in its earliest stages. Through this rigorous analysis, we're pioneering blood tests that identify the body's earliest warning signs of cancer. More at: https://t.co/Z0PjGd0WWC

This November, we unite for Lung Cancer Awareness Month, rallying behind those impacted by the leading cause of cancer death in the United States. Join us in highlighting #LCAM this November. Let's break barriers, spread the word, and drive the research that transforms lives.